Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocrine-Resistant Cancer Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PELP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PELP1 Recombinant Protein (Active Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View PELP1 Products |
| Gene Delivery | PELP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and nuclear translocation assays. |
View PELP1 Products |
| Benchmark Ab | Anti-PELP1 Recombinant Antibody High-affinity positive control for Western Blot, IP, and IHC validation. |
View PELP1 Products |
| Validator | PELP1 siRNA Set Target-specific knockdown verification in ER-positive cell models. |
View PELP1 Products |
| Related Target A | ESR1 (Estrogen Receptor Alpha) Primary functional partner of PELP1; critical for studying genomic/non-genomic ER signaling. |
View ESR1 Products |
| Related Target B | KDM1A (LSD1) Epigenetic reader interacting with PELP1 to regulate oncogenic gene transcription. |
View KDM1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening | Sequence-verified PELP1 interaction domains (LXXLL motifs) with high purity (>95%) for robust in vitro binding assays. |
| Nuclear vs. Cytoplasmic Translocation Tracking | Lentivirus-mediated stable expression of tagged PELP1 to monitor subcellular localization in real-time. |
| Lack of Controls | Recombinant positive control antibodies and validated siRNA sets included for target specificity confirmation. |
| False Positives in Small Molecule Screens | High-purity homolog/off-target panel proteins available for counter-screening. |
Live PELP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PELP1 therapeutics is intensifying, with major players shifting focus from traditional endocrine therapies to small-molecule inhibitors of nuclear receptor coactivators. As first-generation hormone therapies encounter resistance, the next wave of R&D is targeting the PELP1-ER macromolecular complex to bypass mutational resistance in ESR1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Biotech Startups | ER+ Breast Cancer, Ovarian Cancer | In vitro binding assays (Need high-purity PELP1 recombinant protein domains) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Hormone-Resistant Prostate & Breast Cancers | Degradation kinetics assays (Need lentivirus for stable reporter cell line generation) |
| Combination Therapies (with CDK4/6i) | Global Pharma Partners | Refractory Solid Tumors | Synergy validation assays (Need validated siRNA and pathway-related targets like ESR1) |